Ares Genetics is dedicated to improving the diagnosis of microbial infections as well as accelerating antibiotic drug development by leveraging its proprietary collection of pathogen genomes and antibiotic resistance profiles with sophisticated data analysis workflows and interpretation applications.
Ares Genetics was founded in March 2017 as a wholly owned subsidiary of Curetis GmbH, a developer of next-level molecular diagnostic solutions. The company builds on GEAR (GEnetic Antibiotic Resistance and Susceptibility Database): the most comprehensive and ever growing collection of pathogen genomes and antibiotic resistance profiles, which was originally developed and compiled by the Ares Genetics management team at Siemens and acquired by the Curetis Group in late 2016.
Curetis’ Subsidiary Ares Genetics Initiates Development of AI-Powered Infectious Disease Test
Curetis Subsidiary Ares Genetics Launches ARES & CO Pharma Partnering Program
17.-20.09. Vienna, Austria
September 23–26, 2018 - Washington DC area